Cargando…
Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia
BACKGROUND: Homozygous familial hypercholesterolaemia (HoFH) is characterized by a markedly increased risk of premature cardiovascular (CV) events and cardiac death. Lomitapide reduces low-density lipoprotein cholesterol (LDL-C) levels; however, the probable impact on LDL-C goals and CV events is un...
Autores principales: | Blom, Dirk J., Cuchel, Marina, Ager, Miranda, Phillips, Helen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6011273/ https://www.ncbi.nlm.nih.gov/pubmed/29925433 http://dx.doi.org/10.1186/s13023-018-0841-3 |
Ejemplares similares
-
Long‐term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia
por: Larrey, Dominique, et al.
Publicado: (2022) -
Lomitapide treatment in a female with homozygous familial hypercholesterolaemia: a case report
por: Littmann, Karin, et al.
Publicado: (2020) -
Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia
por: Ben-Omran, Tawfeg, et al.
Publicado: (2019) -
A Case Series Assessing the Effects of Lomitapide on Carotid Intima-Media Thickness in Adult Patients with Homozygous Familial Hypercholesterolaemia in a Real-World Setting
por: Blom, Dirk J., et al.
Publicado: (2022) -
Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia
por: Harada-Shiba, Mariko, et al.
Publicado: (2017)